PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
5.28
P/E exceeding 1.5x Medical - Pharmaceuticals median of 1.99. Michael Burry would check for market euphoria. Scrutinize growth expectations.
0.46
P/S less than half the Medical - Pharmaceuticals median of 4.89. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
0.98
P/B 50-90% of Medical - Pharmaceuticals median of 1.66. Mohnish Pabrai would examine if this discount presents opportunity.
-82.86
Negative FCF while Medical - Pharmaceuticals median P/FCF is 0.00. Seth Klarman would investigate cash flow improvement potential.
14.21
P/OCF of 14.21 versus zero operating cash flow in Medical - Pharmaceuticals. Walter Schloss would verify operational quality.
0.98
Fair value ratio 50-90% of Medical - Pharmaceuticals median of 1.66. Mohnish Pabrai would examine if this gap presents opportunity.
4.74%
Earnings yield exceeding 1.5x Medical - Pharmaceuticals median of 1.30%. Joel Greenblatt would investigate if high yield reflects hidden value.
-1.21%
Negative FCF while Medical - Pharmaceuticals median yield is 0.00%. Seth Klarman would investigate cash flow improvement potential.